Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;19(6):526-536.
doi: 10.1007/s11904-022-00639-5. Epub 2022 Dec 2.

Understanding the Evolving Role of Voluntary Medical Male Circumcision as a Public Health Strategy in Eastern and Southern Africa: Opportunities and Challenges

Anna Bershteyn  1 , Edinah Mudimu  2 , Ingrida Platais  3 , Samuel Mwalili  4 , James E Zulu  5 , Wiza N Mwanza  6 , Katharine Kripke  7
Affiliations
Review

Understanding the Evolving Role of Voluntary Medical Male Circumcision as a Public Health Strategy in Eastern and Southern Africa: Opportunities and Challenges

Anna Bershteyn et al. Curr HIV/AIDS Rep. 2022 Dec.

Abstract

Purpose of review: Voluntary male medical circumcision (VMMC) has been a cornerstone of HIV prevention in Eastern and Southern Africa (ESA) and is credited in part for declines in HIV incidence seen in recent years. However, these HIV incidence declines change VMMC cost-effectiveness and how it varies across populations.

Recent findings: Mathematical models project continued cost-effectiveness of VMMC in much of ESA despite HIV incidence declines. A key data gap is how demand generation cost differs across age groups and over time as VMMC coverage increases. Additionally, VMMC models usually neglect non-HIV effects of VMMC, such as prevention of other sexually transmitted infections and medical adverse events. While small compared to HIV effects in the short term, these could become important as HIV incidence declines. Evidence to date supports prioritizing VMMC in ESA despite falling HIV incidence. Updated modeling methodologies will become necessary if HIV incidence reaches low levels.

Keywords: Cost-effectiveness; HIV prevention; Male circumcision; Mathematical modeling; Sexually transmitted infections; Sub-Saharan Africa.

PubMed Disclaimer

Conflict of interest statement

Anna Bershteyn received grants to their institution from the US National Institutes of Health and the Bill and Melinda Gates Foundation. Katharine Kripke received grant to her institution from UNAIDS. Edinah Mudimu, Ingrida Platais, Samuel Mwalili, James E. Zulu, and Wiza N. Mwanza declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Association between cost per HIV infection averted by VMMC and a HIV incidence or bunit cost of VMMC. Unit costs and costs per infection averted were obtained from a study by Kripke et al. [••] which used direct costs and modeled impact of VMMCs performed over 2010–2025 for each country except for Kenya where only the Nyanza region was included. Incidence was obtained at the national level from UNAIDS [81] and for Nyanza from three published estimates [13, 82, 83]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, Controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005;2:e298. doi: 10.1371/journal.pmed.0020298. - DOI - PMC - PubMed
    1. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. The Lancet. 2007;369:657–666. doi: 10.1016/S0140-6736(07)60313-4. - DOI - PubMed
    1. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. The Lancet. 2007;369:643–656. doi: 10.1016/S0140-6736(07)60312-2. - DOI - PubMed
    1. Chiu C, Johnson LF, Jamieson L, Larson BA, Meyer-Rath G. Designing an optimal HIV programme for South Africa: does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 doi: 10.1186/s12889-017-4023-3. - DOI - PMC - PubMed
    1. Meyer-Rath G, van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: evidence from the South African HIV Investment Case. PLoS ONE. 2017;12:e0186496. doi: 10.1371/journal.pone.0186496. - DOI - PMC - PubMed